Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a solid tumour cancer, confirmed through a tissue or cell sample.
- People who are 18 years of age or older.
- People who have at least one tumour measuring 1 cm or more visible on a recent PET/CT scan (a type of imaging scan). A small number of participants may be enrolled even if their tumour does not meet the 1 cm size requirement, as long as it shows activity on the scan.
- People who have had a standard PET/CT scan using a substance called FDG within the past 60 days.
- People who have a tumour tissue sample available that can be tested in a laboratory to check for the presence of a specific protein called uPAR.
- People who are able to understand and are willing to sign a written consent form agreeing to take part in the study.
- Women who could become pregnant must have a negative pregnancy test at the start of the study, and again on the first day of treatment if more than 7 days have passed since the initial test.
- All participants who could potentially father or become pregnant must agree to use highly effective contraception during the treatment period and for at least one month after the last dose.
- Women who are currently breastfeeding must agree to stop breastfeeding before receiving the study drug and must not breastfeed for one month after the last dose.
Who may not be able to join:
- People who have received chemotherapy, radiation therapy (other than a short course for pain relief), or immunotherapy within the 14 days before the study drug is given, or who are still experiencing significant side effects from those treatments.
- People who have received any other radioactive drug treatments or experimental treatments within 4 weeks (or longer, depending on the drug) before the study drug is given.
- People whose bone marrow, liver, or kidneys are not functioning well enough at the time of screening — for example, low blood cell counts, abnormal liver test results, or reduced kidney function (confirm with trial site for specific thresholds).
- People with other serious non-cancer illnesses that the study doctor believes could interfere with the study or affect safety.
- People with cognitive difficulties or other conditions that may prevent them from giving informed consent or following the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Prof. Rod Hicks, MD, Melbourne Theranostic Innovation Centre (MTIC)
Phone: 847-794-8435
Australian sites
03 9454 5800
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To assess dosimetry and biodistribution of MNPR-101-DFO*-89Zr; To assess tumor Standard Uptake Value (SUV) of MNPR-101-DFO*-89Zr; To assess safety of MNPR-101-DFO*-89Zr as assessed by CTCAE 5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.